A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma

SIMPLE SUMMARY: Relapsed or refractory classical Hodgkin lymphoma remains a difficult treatment challenge. Despite responses with the checkpoint inhibitors nivolumab and pembrolizumab, patients eventually progress. Combining other treatments with checkpoint inhibitors may provide more frequent and d...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanel, Walter, Shindiapina, Polina, Bond, David A., Sawalha, Yazeed, Epperla, Narendranath, Voorhees, Timothy, Welkie, Rina Li, Huang, Ying, Behbehani, Gregory K., Zhang, Xiaoli, McLaughlin, Eric, Chan, Wing K., Brammer, Jonathan E., Jaglowski, Samantha, Reneau, John C., Christian, Beth A., William, Basem M., Cohen, Jonathon B., Baiocchi, Robert A., Maddocks, Kami, Blum, Kristie A., Alinari, Lapo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000669/
https://www.ncbi.nlm.nih.gov/pubmed/36900230
http://dx.doi.org/10.3390/cancers15051437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000669/
https://www.ncbi.nlm.nih.gov/pubmed/36900230
http://dx.doi.org/10.3390/cancers15051437

Ejemplares similares